Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLiping SuSouthwest Petroleum UniversityZJZhengming JinSoochow UniversityWYWenjuan YuThe University of Melbourne

Discussion

Loading...

Member takes

Implication

Phase I trial demonstrates promising safety and anti-tumor effects of HDM2005 in relapsed B-NHL and cHL, indicating potential future use in treatment.

Key Points

  • To evaluate the safety, tolerability, and preliminary efficacy of HDM2005 in patients with relapsed or refractory B-NHL and cHL.
  • Phase I clinical trial design enrolling patients with B-NHL and cHL
  • HDM2005 administered intravenously every 3 weeks
  • Patients received doses ranging from 0.3 mg/kg up to 2.75 mg/kg
  • Assessments included dose-limiting toxicity, maximum tolerated dose, and objective responses
  • 29 patients enrolled, with a median age of 60 years
  • Objective response rate was 47.6% across all dose levels
  • Common treatment-related adverse events included neutrophil count decrease and aspartate aminotransferase increase
  • No drug-related deaths occurred; treatment well-tolerated during study

Cite This Study

Su et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d285https://doi.org/10.1182/blood-2025-1808
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.2024 · 14 citations
  2. 2The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study.2024 · 1 citations
  3. 3A phase 1 study of SHR-A1912, a CD79b targeted antibody-drug conjugate (ADC), in patients (pts) with B-cell non-Hodgkin lymphoma (B-NHL).2024
  4. 4Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.2024 · 1 citations
  5. 5First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation2025 · 2 citations